Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

BIO IP News Weekly for June 26, 2009

This week’s BIO IP News Weekly includes an analysis of Professor John Duffy in Business Week, an essay on technology transfer and university-industry collaboration in the Scientist Magazine, updates on USPTO funding and follow-on biologics, a blogger’s look at a U.S. Senator’s struggles to defend intellectual property rights, as well as a link to the recently published 2009 OECD Biotechnology Statistics report summary.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO IP News Weekly for June 19, 2009

This week I include a Nature Biotechnology article on scientific communications, a BBC article on river blindness, and a Heritage Foundation essay on patents.

Patently BIOtech  |  Leave a comment  |  Email This Post

White House Picks Kappos to Lead USPTO

Yesterday the White House nominated David J. Kappos for Under Secretary of Commerce for IP and as the Director of the United States Patent and Trademark Office (USPTO). BIO released its commendation on the nomination today.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO to USA Today: Patents Promote Innovation

Public debate over access to, and use of, genetic technology is a good thing. It requires the consideration of many factors, including coverage and cost, concerns over genetic discrimination and myriad regulatory issues.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Patent Docs: Falsehoods, Distortions and Outright Lies in the Gene Patenting Debate

Patent Docs blog reviewed the most repeated criticisms of the patenting of genetic materials, providing a critical hand to assist non-technical observers of the debate currently swirling around in legal, scientific, and academic circles.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,